article thumbnail

How Merck Is Trying to Keep Disrupters at Bay

Harvard Business Review

EB operates Ilum as a separate business, while still drawing on Merck’s established corporate resources in IT, finance, privacy, compliance, and legal. EB plays the role of a venture capitalist or private-equity board with responsibility to sell, spin-out, or wind-down initiatives that, in practice, are found to be a poor strategic fit.